About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
IP: Ibai Los Arcos Bertiz Collaborators: M Teresa Martin Gomez, Yolanda Villena Ortiz, Javier Gomis Rodriguez, Judith Sacanell Lacasa, Marta Zapata Ortega, David Campany Herrero, Leire Sanchez Corujo Funding agency: Instituto de Salud Carlos III Funding: 37500 Reference: PI23/01467 Duration: 01/01/2024 - 30/06/2028
IP: Francesc Moreso Mateos Collaborators: Gema Ariceta Iraola, Joan López Hellin Funding agency: Instituto de Salud Carlos III Funding: 42900 Reference: PMP22/00119 Duration: 01/01/2023 - 30/06/2026
IP: - Collaborators: Joaquin Seras Franzoso, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C, MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small C Funding agency: Ministerio de Ciencia e Innovación-MICINN Funding: 333099 Reference: CPP2022-009780 Duration: 01/07/2023 - 30/06/2026
IP: - Collaborators: Miriam Izquierdo Sans, Diana Fernandes de Rafael, Simon Schwartz Navarro Funding agency: EUROPEAN COMMISSION Funding: 221390.88 Reference: HYDROTEC_HE-MSCA-PF-GF2022 Duration: 01/01/2024 - 31/12/2026
The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.
